• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by BioAge Labs Inc.

    2/14/25 6:27:36 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    BIOAGE LABS, INC.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    09077V100

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09077V100


    1Names of Reporting Persons

    RA Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,310,589.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,310,589.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,310,589.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    09077V100


    1Names of Reporting Persons

    Peter Kolchinsky
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,310,589.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,310,589.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,310,589.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    09077V100


    1Names of Reporting Persons

    Rajeev Shah
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,310,589.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,310,589.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,310,589.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    09077V100


    1Names of Reporting Persons

    RA Capital Healthcare Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    982,942.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    982,942.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    982,942.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BIOAGE LABS, INC.
    (b)Address of issuer's principal executive offices:

    1445A South 50th Street, Richmond, CA, 94804.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: RA Capital Management, L.P. ("RA Capital") Peter Kolchinsky Rajeev Shah RA Capital Healthcare Fund, L.P. (the "Fund") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116
    (c)Citizenship:

    RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    09077V100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities includes (i) 982,942 shares of Common Stock directly held by the Fund; and (ii) 327,647 shares of Common Stock directly held by the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA Capital Nexus Fund III GP, LLC is the general partner of the Nexus Fund III. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for each of the Fund and the Nexus Fund III and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund or the Nexus Fund III. Each of the Fund and the Nexus Fund III has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in its portfolio, including the shares of the Issuer's Common Stock reported herein. Because each of the Fund and the Nexus Fund III has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, each of the Fund and the Nexus Fund III disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference. The percentage set forth in Row 11 of each Reporting Person's cover page is based upon 35,848,738 shares of the Issuer's Common Stock outstanding as of October 31, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 7, 2024.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2024 and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RA Capital Management, L.P.
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:By Peter Kolchinsky, Authorized Signatory
    Date:02/14/2025
     
    Peter Kolchinsky
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:Peter Kolchinsky
    Date:02/14/2025
     
    Rajeev Shah
     
    Signature:/s/ Rajeev Shah
    Name/Title:Rajeev Shah
    Date:02/14/2025
     
    RA Capital Healthcare Fund, L.P.
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
    Date:02/14/2025
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement

    Get the next $BIOA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    12/5/2025$12.00Underweight → Equal-Weight
    Morgan Stanley
    10/22/2025$10.00Neutral → Buy
    Citigroup
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    12/9/2024$45.00 → $7.00Buy → Neutral
    Citigroup
    10/21/2024$45.00Buy
    Citigroup
    10/21/2024$42.00Buy
    Jefferies
    More analyst ratings

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioAge Labs upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded BioAge Labs from Underweight to Equal-Weight and set a new price target of $12.00

    12/5/25 1:35:23 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs upgraded by Citigroup with a new price target

    Citigroup upgraded BioAge Labs from Neutral to Buy and set a new price target of $10.00

    10/22/25 7:00:32 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on BioAge Labs

    William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

    2/28/25 7:20:24 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

    BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14 Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticipated in first half of 2026 EMERYVILLE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic pro

    12/4/25 9:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference

    EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Thursday, December 4 from 1:30 - 1:55 PM ET, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of

    11/25/25 4:30:00 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs to Present at Jefferies Global Healthcare Conference in London

    EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, November 17 from 7:30 - 7:55 AM ET (12:30 - 1 PM GMT), and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of the webcas

    11/7/25 9:00:00 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rubin Paul D exercised 18,000 shares at a strike of $6.57 and sold $216,000 worth of shares (18,000 units at $12.00) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    12/11/25 4:21:15 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rubin Paul D exercised 68,897 shares at a strike of $4.11 and sold $701,909 worth of shares (68,897 units at $10.19) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    12/5/25 6:20:44 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pande Vijay Satyanand

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    8/11/25 4:14:24 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    SEC Filings

    View All

    SEC Form 144 filed by BioAge Labs Inc.

    144 - BioAge Labs, Inc. (0001709941) (Subject)

    12/9/25 11:23:55 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BioAge Labs Inc.

    144 - BioAge Labs, Inc. (0001709941) (Subject)

    12/4/25 4:30:31 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioAge Labs Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - BioAge Labs, Inc. (0001709941) (Filer)

    12/4/25 9:05:24 AM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

    4/A - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:11:28 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    3/10/25 4:10:37 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

    4 - BioAge Labs, Inc. (0001709941) (Issuer)

    10/3/24 7:19:49 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/14/24 4:15:56 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by BioAge Labs Inc.

    SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

    11/12/24 4:15:53 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by BioAge Labs Inc.

    SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

    10/4/24 8:21:35 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care